Douglas Fambrough, Dicerna CEO (Dicerna via YouTube)

No­vo Nordisk swal­lows Dicer­na and its RNAi pipeline in $3.3B buy­out

Ear­ly this year re­searchers at No­vo Nordisk were beam­ing as they an­nounced the first drug iden­ti­fied in their RNAi al­liance with Dicer­na was head­ed in­to the clin­ic. And now they’re com­ing back for the whole thing.

This morn­ing the Copen­hagen-based phar­ma gi­ant put out word that it is buy­ing Dicer­na $DR­NA — an RNAi pi­o­neer that has had its up and downs over the years — for $3.3 bil­lion. No­vo is pay­ing $38.25 a share — an 80% pre­mi­um.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.